Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03989167
Other study ID # LIO-793111
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 6, 2022
Est. completion date June 6, 2025

Study information

Verified date January 2023
Source University Hospital, Linkoeping
Contact Lars O Karlsson, MD, PhD
Phone +46708784690
Email lars.o.karlsson@regionostergotland.se
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A cluster randomized study in the primary care setting to evaluate a computer-based clinical decision support system to aid in the identification and management of patients with FH. The primary outcome of the study is the number of patients diagnosed with FH at thirty months after study initiation.


Description:

Familial Hypercholesterolemia (FH) is a common cause of premature coronary artery disease (CAD). The prevalence of heterozygous FH has been estimated to be 1 in 500, but recent studies estimate that the prevalence might be as high as 1 in 200. FH is an autosomal-dominant genetic disorder caused by defects in the hepatic uptake and degradation of LDL, primarily due to mutations in the genes coding for the LDL receptor, apolipoprotein B (APOB), proprotein convertase subtilisin kexin type 9 (PCSK9), or LDL-receptor associated protein 1 (LDLRAP1), resulting in high levels of LDL-C and total cholesterol . As a consequence, patients with heterozygous FH have a significantly increased risk of developing premature coronary artery disease (CAD). FH is both underdiagnosed and undertreated, and it is estimated that only a few percent of patients are diagnosed adequately. In Sweden there are no official figures regarding the prevalence of FH, but the patient association for FH recently published a report estimating that only 21 % of the patients in Sweden have been diagnosed. Early treatment with lifestyle changes and high doses of statins has been shown to be effective in reducing the risk of cardiovascular disease, reducing the risk of CAD with 40 - 70 % or more in treated individuals as compared to not treated. The diagnosis of FH has traditionally been based on a combination of clinical signs, family history and cholesterol concentrations. Recently more emphasis has been placed on genetic testing for establishing definitive diagnosis. In Sweden the long-term aim is to diagnose 80 % of all individuals with FH by 2025 according to the "National Guidelines for Cardiac Care 2015" published by The Swedish National Board of Health and Welfare. Clinical decision support (CDS) systems have shown promising results in improving healthcare performance, but results are still conflicting and some studies have not been able to find any clear improvement in quality of care or patient outcomes. Computer-based CDS systems have previously been implemented to aid in the identification and management of patients with FH. The results from these studies are promising; however, to the best of our knowledge, no randomized controlled trial has been conducted investigating the effects of a computer-based CDS in FH. Clinical decision support (CDS) systems are tools that can be used to raise awareness of specific conditions, leading to more individuals being diagnosed and treated in accordance to guidelines. Clinical decision support for Familial hypercholesterolemia (CDS-FH) is a cluster randomized trial that will be conducted in the primary care setting in the county of Östergötland, Sweden. The primary care clinics participating in the study will be randomized 1:1 to CDS intervention or to control. Before the study is initiated all of the physicians working at the participating primary care clinics will receive information regarding FH and the associated risk for cardiovascular disease. Information regarding the study, FH and technical aspects of CDS-FH will be available for the participating physicians throughout the entire study period. The investigators intend to include all primary care clinics in the County of Östergötland (n = 45). Participation is non-compulsory. The population in the County of Östergötland is 467 158 inhabitants (December 2020). The CDS-FH has been developed in collaboration between Cambio Healthcare systems and Evry Healthcare Systems (the suppliers of the EHR in the county of Östergötland), the Cardiology Department at Linköping University hospital, Uppsala University and primary care professionals in the counties of Östergötland. CDS-FH is activated when a physician attests a cholesterol lab result in the laboratory section of the EHR. If the patient has high levels of total cholesterol or LDL-C (Total cholesterol > 8 mmol/l or LDL-C > 5.5 mmol/l, adjusted for age strata and ongoing treatment with cholesterol lowering medications), in combination with other risk factors for FH (according to the Dutch Lipid Clinic Network (DLCN) criteria), a screen warning will appear informing the responsible physician that the patient may have FH. On the other hand, if the patient does not have elevated levels of total cholesterol or LDL-C, or if any exclusion criteria are met, no screen warning will appear when the cholesterol lab-result is attested. By clicking on the warning screen that was activated due to high cholesterol levels, a window will open displaying an overview of the patient's cholesterol values and prior diagnoses recorded in the EHR that are consistent with premature CAD. A link to further information regarding FH from the Swedish National Board of Health and Welfare is also provided. The physician is thereafter urged to consider sending a referral to the local FH clinic, and to prescribe or intensify treatment with lipid lowering medication. The referral is automatically generated by the CDS application and the CDS also makes a short note in the EHR regarding the suspicion of FH. The physician can chose to postpone the decision or make a decision to refrain from sending the referral. In case the choice is made to refrain from sending the referral the physician is asked to specify why in a mandatory short text comment, in order to monitor the main reasons for not continuing the investigation of suspected FH. The FH clinic will receive all the referrals generated by the CDS-FH and all referrals generated as part of the regular routine in the region. All patients diagnosed with FH at the FH-clinic will be registered and assigned to either the CDS intervention group or to the control group. Any relatives currently residing in the County of Östergötland or in the County of Uppsala that are diagnosed with FH as a result of cascade screening will also be registered at the FH-clinic and assigned to either the CDS intervention group or to the control group. The primary outcome of the study is the number of probands (index patients) diagnosed with FH at thirty-four months after study initiation.


Recruitment information / eligibility

Status Recruiting
Enrollment 460000
Est. completion date June 6, 2025
Est. primary completion date June 6, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria - Primary care centers in the county of Östergötland. Exclusion Criteria - Primary care centers not using the Cambio Cosmic Electronic Health Record System.

Study Design


Intervention

Other:
Clinical decision support
Computer-based support tool for identification of patients with high levels of total cholesterol or LDL-C, at high risk of being affected by FH.

Locations

Country Name City State
Sweden Universitetssjukhuset i Linköping Linköping

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Linkoeping

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary The number of patients diagnosed with FH (ICD E78.0A) at thirty months after study initiation The number of probands (index patients) diagnosed with FH (ICD E78.0A) at thirty months after study initiation.The diagnosis of FH will be based on the Dutch Lipid Clinic Network (DLCN) criteria. All patients found to have definite or probable FH according to the DLCN criteria will be diagnosed with FH. This endpoint excludes patients diagnosed secondary to cascade screening. 30 months after study initiation
Secondary Number of patients diagnosed with FH (ICD E78.0A) based on genetic testing. We will investigate the number of patients diagnosed with FH based on the presence of a pathogenic FH-causing mutation and evaluate a possible difference between the CDS intervention group and the control group. 30 months after study initiation
Secondary Number of patients diagnosed with FH (ICD E78.0A) including cascade screening. To evaluate the full effect of the intervention we will investigate the number of patients diagnosed with FH including any relatives to the proband that are diagnosed secondary to cascade screening. The cascade screening will continue in parallel with the inclusion of new probands throughout the study period. 30 months after study initiation
Secondary Cost-effectiveness of using the Clinical decision support for Familial hypercholesterolemia We will calculate the cost of implementation and usage of the CDS-FH as well as annual fees and costs related to administration of the CDS-FH. The costs-effectiveness will then be calculated in relation to the potential cost-reducing long-term effects of improvements in the identification and management of FH patients. 30 months after study initiation
Secondary Reasons for deviation We will investigate the main reasons for not sending a referral to the FH-clinic when recommended to do so by the CDS. The mandatory question in the CDS system regarding the reason for refraining from sending the referral will be analysed to identify the main reasons stated by the physicians. 30 months after study initiation
See also
  Status Clinical Trial Phase
Terminated NCT00384293 - Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED) Phase 3
Completed NCT04722068 - Regeneron 1331 Kinetics Sub-Study HoFH N/A
Completed NCT04118348 - Evaluating the Efficacy of Pediatric Lipid Screening Alerts N/A
Completed NCT00000594 - NHLBI Type II Coronary Intervention Study Phase 3
Completed NCT04526457 - Is Family Screening Improved by Genetic Testing of Familial Hypercholesterolemia N/A
Completed NCT01753232 - Safety and Efficacy of the DALI LDL-adsorber and MONET Lipoprotein Filter N/A
Completed NCT03018678 - Screening Protocol for a Gene Therapy Trial in Subjects With Homozygous Familial Hypercholesterolemia
Completed NCT00134485 - Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia Phase 3
Completed NCT00134511 - Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder Phase 3
Recruiting NCT04073797 - PET Imaging of Inflammation and Lipid Lowering Study N/A
Terminated NCT01583647 - A Study of Extended-release (ER) Niacin/Laropiprant in Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0524A-158) Phase 1
Completed NCT00515307 - Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia Phase 1
Recruiting NCT04656028 - Genetic Testing and Motivational Counseling for FH N/A
Terminated NCT00092833 - Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED) Phase 3
Active, not recruiting NCT04837638 - Diet Quality and Coronary Artery Calcification in Adults With Heterozygous Familial Hypercholesterolemia
Completed NCT00280995 - Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Completed NCT06231459 - Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 in Familial Hypercholesterolemia Phase 4
Completed NCT01524289 - Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) Phase 3
Completed NCT00281008 - Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy Phase 2
Completed NCT03795038 - Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI N/A